Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | F2 | P00734 | 2/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564086 | 0.83 | HTT (1.00) | HTTALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL11185956 | 0.82 | ALDH1A1 (0.67) | HTTALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL1179639 | 0.81 | HTT (0.71) | HTTALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL30630025 | 0.81 | HTT (0.71) | HTTALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL3618541 | 0.81 | MAPT (1.00) | HTTALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL11350758 | 0.81 | HTT (0.60) | HTTALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL1178744 | 0.79 | HTT (0.67) | HTTALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL12886466 | 0.79 | HTT (0.67) | HTTALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL26546139 | 0.77 | HTT (0.65) | HTTALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL8980136 | 0.73 | ALDH1A1 (0.64) | ALDH1A1MAPTKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-7528162-B2 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2009-05-05 | — | — | US | disclosed |
| EP-1268435-B1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB 1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2006-11-22 | — | — | EP | disclosed |
| EP-1429761-B1 | NOVEL 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2006-11-08 | — | — | EP | disclosed |
| EP-1373216-B1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2004-12-15 | — | — | EP | disclosed |
| EP-1268435-A1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB 1-ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2003-01-02 | — | — | EP | disclosed |
| US-6476060-B2 | DRUG ABUSE; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS; CARDIOVASCUALR DISORDERS | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2002-11-05 | — | — | US | disclosed |
| WO-2002076949-A1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2002-10-03 | — | — | WO | disclosed |
| US-20010053788-A1 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2001-12-20 | — | — | US | disclosed |
| WO-2001070700-A1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2001-09-27 | — | — | WO | disclosed |
| US-4289876-A | HISTAMINE H2 RECEPTOR BLOCKING AGENTS, ANTIULCER | BRISTOL-MYERS COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| US-4282363-A | ANTIULCER | BRISTOL-MYERS COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
| US-4250316-A | Pyridyl guanidine anti-ulcer agents | BRISTOL-MYERS COMPANY (US) | 1981-02-10 | — | — | US | disclosed |
| US-4203909-A | ANTIULCER | BRISTOL-MYERS COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4200578-A | ANTIULCER AGENTS, BLOCKING AGENTS, ANTISECRETORY AGENTS | BRISTOL-MYERS COMPANY (US) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053788-A1 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | CNR1, CNR2, CBR3 | HTT 2041/4885ALDH1A1 527/4885MAPT 3867/4885 |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | HTT 1252/4885ALDH1A1 1520/4885MAPT 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.